The detected biomolecular binding events include, for example, nucleic acid hybridizations, antibody/antigen binding, and receptor/ligand binding.

The metal-labelled species may be formed by the binding of an analyte to be detected with a metal-labelled binding partner, such as an antibody or antigen binding fragment thereof.

Antibodies, including bispecific antibodies, are preferred binding agents.

The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies.

The cell binding agent is preferably an antibody.

The binding molecule is preferably an antibody.

Disclosed is an anti-idiotypic antibody which reacts with an anti-CA125 antibody and competes with CA125 in its binding to said anti-CA125 antibody.

The binding partner can be, e.g., a synthebody or a part thereof.

For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody.

The compositions relate to a fusion protein having a binding moiety such as an antibody, an antigen binding fragment of an antibody or an antibody mimetic that recognizes the endogenous or target protein.

For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody.

The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers.

Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided.

The present invention relates to monoclonal antibody 4B5 and antigen binding fragments that specifically bind to the antibodies specific for GD2.

This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives.